Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma.
BACKGROUND
Advances in outpatient and supportive care and increased pressure on hospital bed usage has led to the investigation of hospital in the home (HITH) management following autologous haematologous stem cell transplantation (AutoHSCT) for patients with multiple myeloma or lymphoma.


METHODS
The Newcastle Mater Hospital Haematology Unit together with the Mater Acute Care Community Service (MACCS) developed a protocol for HITH care following AutoHSCT.


RESULTS
Clinical outcomes of the protocol were audited: 40% (13) of patients were suitable candidates for HITH care post transplantation. Of these 84.6% (11) were readmitted to the haematology unit within seven days of discharge from hospital.


CONCLUSIONS
Our preliminary experience suggests that with adequate infrastructure support and rigorous patient selection this model of care is both safe and feasible.
Johnson
Wendy
W
Mater Acute Care Community Service, Newcastle Mater Hospital, New South Wales, Australia.
Kerridge
Ian
I
Milton
Cathie
C
Carr
Debbie
D
Enno
Arno
A
Bray
Louisa
L
Booth
Angela
A
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D002985:Clinical Protocols; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018575:Home Care Services, Hospital-Based / Q000592:standards*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008223:Lymphoma / Q000601:surgery*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000601:surgery*; D009517:New South Wales; D009731:Nursing Audit; D010043:Outcome and Process Assessment, Health Care; D010359:Patient Readmission; D033581:Stem Cell Transplantation / Q000451:nursing*; D019172:Transplantation Conditioning / Q000379:methods; D014182:Transplantation, Autologous
D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D003561:Cytarabine; D005047:Etoposide; D008130:Lomustine; D003520:Cyclophosphamide; D008558:Melphalan